VNS Therapy System
LivaNova USA, Inc. · Decision date Aug 12, 2026
What did the FDA approve?
FDA records P970003/S249 as a supplement to PMA P970003, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 12, 2026.
FDA approval order statement
approval for 1) changing the term partial onset seizures to focal onset seizures in the Indications for Use, 2) changing the term sudden unexplained death to sudden unexpected death, 3) removing the Warning label associated with SUDEP-related information and moving the SUDEP-related information from the Warnings section to the Clinical Studies section of the Physicians Manual, 4) aligning the SUDEP-related information in the Patient Guide with the Physicians Manual and removing the Caution label associated with SUDEP-related information.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Neurology
- Decision date
- Aug 12, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P970003/S249
- Regulatory pathway
- PMA supplement
- Applicant
- LivaNova USA, Inc.
- Product code
- LYJ
- Decision code
- APPR
- Decision date
- Aug 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, autonomic nerve, implanted for epilepsy.
- Applicant
- LivaNova USA, Inc.
- Product code
- LYJ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P970003. Subsequent supplements may change the device or its indications.
FDA decision timeline
P970003 · Original PMA
VNS THERAPY SYSTEM
P970003/S249 received
Application receipt date recorded by FDA.
P970003/S248 · Related supplement
VNS Therapy System
P970003/S250 · Related supplement
VNS Therapy System
P970003/S251 · Related supplement
VNS Therapy Model 3100 Programmer, VNS Therapy Model 2000 Programming Wand
P970003/S252 · Related supplement
VNS THERAPY SYSTEM
P970003/S253 · Related supplement
VNS Therapy System
P970003/S249 · FDA decision
Normal 180 Day Track
P970003/S254 · Related supplement
VNS Therapy System
Timeline entries are records held by MedtechLedger for P970003. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P970003
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
VNS THERAPY SYSTEMP970003 | LivaNova USA, Inc. | PMA approval | Jul 16, 1997 | FDA |
VNS Therapy SystemP970003/S248 | LivaNova USA, Inc. | PMA supplement | Sep 5, 2025 | FDA |
VNS Therapy SystemP970003/S250 | LivaNova USA, Inc. | PMA supplement | Sep 12, 2025 | FDA |
| LivaNova USA, Inc. | PMA supplement | Nov 25, 2025 | FDA | |
VNS THERAPY SYSTEMP970003/S252 | LivaNova USA, Inc. | PMA supplement | Dec 17, 2025 | FDA |
VNS Therapy SystemP970003/S253 | LivaNova USA, Inc. | PMA supplement | Mar 4, 2026 | FDA |
VNS Therapy SystemP970003/S254 | LivaNova USA, Inc. | PMA supplement | Oct 2, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
LivaNova USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 100 Cyberonics Blvd., Houston, TX, 77058
Sources and methodology
- Original FDA record: P970003/S249
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



